Zydus Lifesciences Financial Statements

Zydus Lifesciences (ZYDUSLIFE) reported revenue of ₹276.58B in FY2026 with net income of ₹51.24B. Total assets stood at ₹524.07B. Net worth was ₹271.11B (₹27,111 Cr) and free cash flow was -₹5.55B.

Zydus Lifesciences Income Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Revenue		232.42B	276.58B
Cost of Rev. Cost of Revenue		-67.08B	-72.93B
Gross Profit		165.34B	203.65B
SGA Sales, General & Admin		-36.81B	-113.81B
Op. Income Operating Income		57.73B	75.77B
PBT Profit Before Tax		60.27B	67.18B
Net Income		45.26B	51.24B
Dil. Shares Diluted Shares		1.01B	1.01B
Diluted EPS		44.97	50.09

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Zydus Lifesciences's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Zydus Lifesciences Balance Sheet

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Curr. assets Total current assets		170.46B	199.06B
Non-curr. assets Total non-current assets		201.56B	325.01B
Total assets		372.02B	524.07B
Curr. liabilities Total current liabilities		90.42B	157.12B
Non-curr. liab. Total non-current liabilities		18.02B	71.13B
Total liabilities		108.43B	228.24B
Total equity		263.58B	295.82B
Total liab. & eq. Total liabilities & equity		372.02B	524.07B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Zydus Lifesciences's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Zydus Lifesciences Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2025 – FY 2026

Item	Chart	2025	2026
Net Income		60.27B	66.21B
Operating CF Cash flow Operating Activities		67.77B	21.17B
Capex Investments in PPE		-17.13B	-26.72B
Investing CF Cash flow Investing Activities		-83.72B	-82.96B
Dividend Paid		-3.03B	-11.06B
Financing CF Cash flow Financing Activities		20.14B	58.07B
Cash (start) Cash at beginning of period		4.13B	8.27B
Cash (end) Cash at end of period		8.27B	8.55B
FCF Free Cash Flow		50.64B	-5.55B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Zydus Lifesciences's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2026